IDT (ASX) IDT media thread

Originally posted by dannyleb: ↑

Well it turned out south Australia facility doesn't even have the finish and fill facility (which cost 300mullions to set up and few years to get it approved).

Now it s clear SA FACILITY has no chance getting moderna or any other vaccines as they don't have finish and fill facility.

Idt has a facility capable producing 100 millions doses a year, more than enough for Australia until the Monash vaccine6gets the go.

=============================

Skip to content

Cosmos Magazine

MENU AND WIDGETS

A Victorian-made mRNA vaccine gets to the next stage
While other types of vaccine, like AstraZeneca, are currently being made in Australia, there is as yet no large-scale way to make mRNA vaccines (such as the Pfizer or Moderna vaccines), meaning these vaccines have to be shipped in from overseas.

But a team of Victorian researchers have just announced they’ve developed the first local mRNA vaccine for COVID-19, which is heading into Phase I clinical trials.

A Melbourne plant run by IDT Australia has produced 450 doses of the vaccine, which will be given to 150 people to test its safety, and whether it provokes an immune response. Results from the trial are expected in 2022.

The vaccine was co-developed by the Monash Institute of Pharmaceutical Sciences (MIPS), the Doherty Institute and IDT Australia, and was funded by the Victorian government.

“This is a major milestone in Australia’s ability to manufacture homegrown COVID-19 mRNA vaccines,” says Professor Terry Nolan, head of the vaccine and immunisation research group at the Doherty Institute.

“We are excited to commence Phase 1 clinical trials of this candidate, along with the protein vaccine candidate developed by the Doherty Institute, in the coming months.”

Australia can’t yet make any mRNA vaccines onshore at scale, because there isn’t a facility that has all the equipment and expertise needed to make mRNA vaccines from end-to-end – although a number of places are capable of doing parts of the process.

For instance, BioCina, which officially opened its plant in Adelaide last week, has microbial fermentation equipment with the right certification (Good Manufacturing Process, or GMP), which is needed to make the mRNA. But it’s still working on the subsequent stages of the process – lipid nanoparticle coating, which stabilises the mRNA so it can go into human bodies – and it doesn’t have a fill/finish facility, which safely bottles the vaccines for distribution.

The IDT plant, in Boronia in Melbourne, doesn’t yet have microbial equipment and skills to make mRNA at scale (although it did make the mRNA for the 450 trial vaccines). It can, however, do the latter stages of the vaccine making – lipid nanoparticle coating, and bottling of the vaccine – using equipment it purchased from Canada.

Both companies, along with several others, have put in a bid with the federal government to fund the expansion of their facilities, so they can cover the other parts of the vaccine manufacture process.

“Because of the high cost of buying in vaccine from overseas, and the potential to be at the back of the queue for future pandemics, we urgently need to build expertise, capacity and capability in Australia to make mRNA vaccines and RNA therapeutics more broadly,” says Associate Professor Archa Fox, a researcher at the University of Western Australia and president of the RNA network of Australasia.

“This announcement by MIPS/Doherty/IDT is a significant step forwards towards creating our first homegrown Australian mRNA vaccine.”

“We might well see from this a new mRNA COVID-19 vaccine come to market. This alone would be an important development as we are faced with an ongoing demand for vaccines to fight the pandemic,” says Professor Thomas Preiss, leader of the RNA Biology Group in the College of Health & Medicine at the Australian National University.

“Equally importantly, RNA has plenty of potential as a therapeutic beyond vaccines. The breakthrough in Melbourne then shows us that, as a country, we have the wherewithal to build an RNA R&D ecosystem that can efficiently develop these new drugs. The hope now is that we will furthermore put them into local production and service a growing global market.”

Posted on1 December 2021AuthorEllen PhiddianCategoriesCOVID, Australia, Health, News
Post navigation
PREVIOUSPrevious post:To see the world in a grain of salt
NEXTNext post:Back on the rails
Exit mobile version

Expand

the article also says that IDT doesn't have a microbial fermentation capacity

No.	Vol.	Price($)
5	387306	11.5¢

No.

Vol.

Price($)

387306

11.5¢

Price($)	Vol.	No.
12.5¢	150882	2

Price($)

Vol.

No.

12.5¢

150882

No.	Vol.	Price($)
4	187306	0.115
11	567765	0.110
4	509533	0.105
1	30000	0.099
1	5500	0.096

No.

Vol.

Price($)

187306

0.115

567765

0.110

509533

0.105

30000

0.099

5500

0.096

Price($)	Vol.	No.
0.125	150882	2
0.130	178203	6
0.140	71150	3
0.145	56900	2
0.150	127098	3

Price($)

Vol.

No.

0.125

150882

0.130

178203

0.140

71150

0.145

56900

0.150

127098

(20min delay)
Last 12.0¢		Change 0.005(4.35%)		Mkt cap ! $51.58M

Open	High	Low	Value	Volume
11.5¢	12.0¢	11.5¢	$89.75K	754.6K

the article also says that IDT doesn't have a microbial...

NRW Holdings inks $109M deal with BHP for works at Jimblebar

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Issues emerging as Australian companies tackle critical minerals challenge

Defence MOU for propulsion systems pushes Aurora Lab shares higher

ASX Market Open: ASX200 to open flattish after Wall Street weakens on hot US inflation data | October 11, 2024

Tigers Realm's US$49M sale of Russian assets – to a Kremlin-adjacent billionaire – set to go ahead

Ragnar impressed by 11.55 metre pegmatite in Sweden, anticipating further mineralisation

Sunshine Metals kicks off copper gold drilling at Truncheon; Highway East targets

Cauldron Energy reports "excellent" uranium assays in latest drill run

Week 41 Wrap: HotCopper asks “Back to Mongolia?” for Elixir; US CPI comes in at 2.4%; eyes still on China

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

the article also says that IDT doesn't have a microbial...

Top Stories

NRW Holdings inks $109M deal with BHP for works at Jimblebar

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Issues emerging as Australian companies tackle critical minerals challenge

Defence MOU for propulsion systems pushes Aurora Lab shares higher

ASX Market Open: ASX200 to open flattish after Wall Street weakens on hot US inflation data | October 11, 2024

Tigers Realm's US$49M sale of Russian assets – to a Kremlin-adjacent billionaire – set to go ahead

Ragnar impressed by 11.55 metre pegmatite in Sweden, anticipating further mineralisation

Sunshine Metals kicks off copper gold drilling at Truncheon; Highway East targets

Cauldron Energy reports "excellent" uranium assays in latest drill run

Week 41 Wrap: HotCopper asks “Back to Mongolia?” for Elixir; US CPI comes in at 2.4%; eyes still on China

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News